LENZ
LENZ Therapeutics, Inc.
There isn't enough reported data to score LENZ yet.
LENZ Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
LENZ's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
LENZ PE Valuation
LENZ has no meaningful PE right now: it lost money over the past year.
LENZ Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LENZ's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LENZ Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$7.11 | +$8.43 |
| Q2 2024 | -$9.46 | +$6.50 |
| Q1 2024 | -$15.85 | -$3.32 |
| Q4 2023 | -$15.33 | -$2.45 |
LENZ is still losing money, but far less than before: $4.53 per share over the past year, against $15.96 at its worst in mid-2023.
LENZ Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.4M | -73% |
| Q2 2026 | $5.5M | +9.7% |
LENZ's revenue has slid since its 2025 peak: $3M last quarter, down 73% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -973% | -822 points |
| Q2 2026 | -623% | -286 points |
| Q1 2026 | -2322% | N/A |
| Q4 2025 | -2422% | N/A |
| Q3 2025 | -151% | N/A |
| Q2 2025 | -337% | N/A |
LENZ's operating margin was −973% last quarter, down 822 points from the same quarter a year ago.
LENZ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$22.3M | -$13.3M |
| Q2 2026 | -$38.7M | -$27M |
| Q1 2026 | -$33.6M | -$17.4M |
| Q4 2025 | -$33.1M | -$23.8M |
| Q3 2025 | -$9M | +$1.7M |
| Q2 2025 | -$11.7M | +$4.2M |
| Q1 2025 | -$16.2M | +$7.8M |
| Q4 2024 | -$9.2M | +$36.7M |
LENZ has burned cash in almost every quarter: −$128M over the past year, against −$46M the year before.
LENZ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +45.8K shares |
| 1 year | +10% | +2.9M shares |
| 3 years | +288% | +23.3M shares |
| 5 years | +279% | +23.1M shares |
LENZ has 31M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q2 2020 | — |
LENZ Net Leverage
LENZ's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LENZ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.6 | Neutral |
| Stochastic | 17.3 | Oversold |
LENZ's weekly RSI is 38 (neutral) and its Stochastic is 17 (oversold).
LENZ PE vs Healthcare Sector
LENZ has no meaningful PE right now: it lost money over the past year.
LENZ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 16% above |
| 20 week MA | $4.50 | 9.1% below |
| 50 week MA | $9.12 | 55% below |
| 100 week MA | $19.7 | 79% below |
| 200 week MA | $18.1 | 77% below |
LENZ has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 77% below its 200-week average.
LENZ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $87.6 | $54.7 | -37% |
| 2022 | $54.7 | $13.4 | -76% |
| 2023 | $13.4 | $12.4 | -7.3% |
| 2024 | $12.4 | $31.3 | +153% |
| 2025 | $31.3 | $16.9 | -46% |
| 2026 YTD | $16.9 | $4.09 | -76% |
LENZ's yearly returns have swung widely, from +153% in 2024 to −76% in 2022. It's down 76% so far in 2026.